OBJECTIVES: To estimate efficacy of a visual triage of human papillomavirus (HPV)-positive women to either immediate cryotherapy or referral if not treatable (eg, invasive cancer, large precancers). METHODS: We evaluated visual triage in the HPV-positive women aged 25 to 55 years from the 10,000-woman Guanacaste Cohort Study (n = 552). Twelve Peruvian midwives and 5 international gynecologists assessed treatability by cryotherapy using digitized high-resolution cervical images taken at enrollment. The reference standard of treatability was determined by 2 lead gynecologists from the entire 7-year follow-up of the women. Women diagnosed with histologic cervical intraepithelial neoplasia grade 2 or worse or 5-year persistence of carcinogenic HPV infection were defined as needing treatment. RESULTS: Midwives and gynecologists judged 30.8% and 41.2% of women not treatable by cryotherapy, respectively (P < 0.01). Among 149 women needing treatment, midwives and gynecologists correctly identified 57.5% and 63.8% (P = 0.07 for difference) of 71 women judged not treatable by the lead gynecologists and 77.6% and 59.7% (P < 0.01 for difference) of 78 women judged treatable by cryotherapy. The proportion of women judged not treatable by a reviewer varied widely and ranged from 18.6% to 61.1%. Interrater agreement was poor with mean pairwise overall agreement of 71.4% and 66.3% and kappa's of 0.33 and 0.30 for midwives and gynecologists, respectively. CONCLUSIONS: In future "screen-and-treat" cervical cancer prevention programs using HPV testing and cryotherapy, practitioners will visually triage HPV-positive women. The suboptimal performance of visual triage suggests that screen-and-treat programs using cryotherapy might be insufficient for treating precancerous lesions. Improved, low-technology triage methods and/or improved safe and low-technology treatment options are needed.
OBJECTIVES: To estimate efficacy of a visual triage of human papillomavirus (HPV)-positive women to either immediate cryotherapy or referral if not treatable (eg, invasive cancer, large precancers). METHODS: We evaluated visual triage in the HPV-positive women aged 25 to 55 years from the 10,000-womanGuanacaste Cohort Study (n = 552). Twelve Peruvian midwives and 5 international gynecologists assessed treatability by cryotherapy using digitized high-resolution cervical images taken at enrollment. The reference standard of treatability was determined by 2 lead gynecologists from the entire 7-year follow-up of the women. Women diagnosed with histologic cervical intraepithelial neoplasia grade 2 or worse or 5-year persistence of carcinogenic HPV infection were defined as needing treatment. RESULTS: Midwives and gynecologists judged 30.8% and 41.2% of women not treatable by cryotherapy, respectively (P < 0.01). Among 149 women needing treatment, midwives and gynecologists correctly identified 57.5% and 63.8% (P = 0.07 for difference) of 71 women judged not treatable by the lead gynecologists and 77.6% and 59.7% (P < 0.01 for difference) of 78 women judged treatable by cryotherapy. The proportion of women judged not treatable by a reviewer varied widely and ranged from 18.6% to 61.1%. Interrater agreement was poor with mean pairwise overall agreement of 71.4% and 66.3% and kappa's of 0.33 and 0.30 for midwives and gynecologists, respectively. CONCLUSIONS: In future "screen-and-treat" cervical cancer prevention programs using HPV testing and cryotherapy, practitioners will visually triage HPV-positive women. The suboptimal performance of visual triage suggests that screen-and-treat programs using cryotherapy might be insufficient for treating precancerous lesions. Improved, low-technology triage methods and/or improved safe and low-technology treatment options are needed.
Authors: R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton Journal: Rev Panam Salud Publica Date: 1997-05
Authors: Lynette Denny; Louise Kuhn; Michelle De Souza; Amy E Pollack; William Dupree; Thomas C Wright Journal: JAMA Date: 2005-11-02 Impact factor: 56.272
Authors: M Concepción Bratti; Ana C Rodríguez; Mark Schiffman; Allan Hildesheim; Jorge Morales; Mario Alfaro; Diego Guillén; Martha Hutchinson; Mark E Sherman; Claire Eklund; John Schussler; Julie Buckland; Lidia A Morera; Fernando Cárdenas; Manuel Barrantes; Elmer Pérez; Thomas J Cox; Robert D Burk; Rolando Herrero Journal: Rev Panam Salud Publica Date: 2004-02
Authors: Julia C Gage; Ana Cecilia Rodriguez; Mark Schiffman; Francisco M Garcia; Rodney L Long; Scott R Budihas; Rolando Herrero; Robert D Burk; Jose Jeronimo Journal: J Low Genit Tract Dis Date: 2009-07 Impact factor: 1.925
Authors: Catherine C Godfrey; Pamela M Michelow; Mandana Godard; Vikrant V Sahasrabuddhe; Janice Darden; Cynthia S Firnhaber; Neal T Wetherall; James Bremer; Robert W Coombs; Timothy Wilkin Journal: Am J Clin Pathol Date: 2013-12 Impact factor: 2.493
Authors: Alex K Mezei; Heather N Pedersen; Stephen Sy; Catherine Regan; Sheona M Mitchell-Foster; Josaphat Byamugisha; Musa Sekikubo; Heather Armstrong; Angeli Rawat; Joel Singer; Gina S Ogilvie; Jane J Kim; Nicole G Campos Journal: BMJ Open Date: 2018-06-12 Impact factor: 2.692